- Home
- SCLX vs LTRN Comparison
SCLX vs LTRN Comparison
Compare SCLX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- LTRN
- Stock Information
- Founded
- SCLX 2011
- LTRN 2013
- Country
- SCLX United States
- LTRN United States
- Employees
- SCLX N/A
- LTRN N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- SCLX Health Care
- LTRN Health Care
- Exchange
- SCLX Nasdaq
- LTRN Nasdaq
- Market Cap
- SCLX 33.9M
- LTRN 36.0M
- IPO Year
- SCLX N/A
- LTRN 2020
- Fundamental
- Price
- SCLX $6.38
- LTRN $3.33
- Analyst Decision
- SCLX Strong Buy
- LTRN Strong Buy
- Analyst Count
- SCLX 3
- LTRN 1
- Target Price
- SCLX $367.50
- LTRN $25.00
- AVG Volume (30 Days)
- SCLX 100.7K
- LTRN 227.0K
- Earning Date
- SCLX 08-12-2025
- LTRN 08-07-2025
- Dividend Yield
- SCLX N/A
- LTRN N/A
- EPS Growth
- SCLX N/A
- LTRN N/A
- EPS
- SCLX N/A
- LTRN N/A
- Revenue
- SCLX $50,710,000.00
- LTRN N/A
- Revenue This Year
- SCLX $107.00
- LTRN N/A
- Revenue Next Year
- SCLX $82.52
- LTRN N/A
- P/E Ratio
- SCLX N/A
- LTRN N/A
- Revenue Growth
- SCLX 7.79
- LTRN N/A
- 52 Week Low
- SCLX $3.60
- LTRN $2.55
- 52 Week High
- SCLX $73.50
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- SCLX 60.64
- LTRN 63.16
- Support Level
- SCLX $6.00
- LTRN $3.15
- Resistance Level
- SCLX $6.76
- LTRN $3.31
- Average True Range (ATR)
- SCLX 0.42
- LTRN 0.17
- MACD
- SCLX 0.11
- LTRN 0.06
- Stochastic Oscillator
- SCLX 82.06
- LTRN 87.14
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.